Botulinum A Toxin in the Treatment of Patients With Painful Bladder Syndrome
Status:
Unknown status
Trial end date:
2011-09-01
Target enrollment:
Participant gender:
Summary
Previous clinical observations showed that Botulinum A toxin (BoNT/A) has also an
antinociceptive effect and can control the neuropathic pain.
In the urologic field, recent in in vitro and in in vivo studies demonstrated that the
neurotoxin is able to inhibit the release of several neurotransmitters from the bladder
afferent fibers and urothelium. These neurotrasmitters as SP, CGRP, ATP, NGF and
Prostaglandins are involved in neurogenic inflammation. Thus, it is reasonable to hypothesize
that patients with affected by painful bladder syndrome (PBS) could benefit from BoNT/A
intravesically administered.
The aim of the study is to investigate the clinical and urodynamic effects of an intravesical
treatment with BoNT/A in patients affected by PBS associated with increased urinary
frequency, who are refractory to conventional treatments. This treatment will be compared to
bladder over distention, which is considered a conventional therapy.
Phase:
Phase 4
Details
Lead Sponsor:
University Of Perugia
Treatments:
abobotulinumtoxinA Botulinum Toxins, Type A incobotulinumtoxinA onabotulinumtoxinA